Bioventix produces sheep monoclonal antibodies for diagnostic tests. It has been listed on UK PLUS Stock Exchange since April 2010.
Bioventix’s portfolio of antibodies includes those for use in thyroid hormone, estrodial testing (fertility testing), testing for testosterone levels, testing of saliva for cannabis/marijuana abd testing for Vitamin D deficiency.
Its main source of revenue comes from direct sale of purified antibodies or from royalties from customer product sales that contains Bioventix’s antibody.
The Company is led by its CEO, Peter Harrison, who led a management buy-out that resulted in the formation of Bioventix. He has worked in the antibody field since 1986 with rich experience in development and commercialization of antibody technologies.